CONICET | Buscador de Institutos y Recursos Humanos

This multinational observational study is being performed to gather data that reflect current practices in the management of people with diabetes in different areas of the world and to evaluate compliance with international guidelines. Data is being collected from type 1 diabetic patients (¡Ã18 years) in 1-year cycles (a 2-week cross-sectional period followed by a 9-month longitudinal period) for 5 years. Data from the first cross-sectional period are currently available from 1327 people (51% men) in 11 countries in Eastern Europe, Asia, and Latin America. The mean age was 36¡¾13 years, mean BMI 23¡¾4 kg/m¡ù2 (for both men and women) and mean disease duration 11 years. Mean HbA¡ø1c was 8.2¡¾1.96% and 27% of people had an HbA¡ø1c <7%. Mean FBG (laboratory) was 161¡¾75 mg/dL. Mean systolic/diastolic blood pressure was 122/75 mmHg. Target treatment levels were achieved for LDL (<100 mg/dL) in 41% of people, for HDL (>40 mg/dL) in 81%, and for triglycerides (<150 mg/dL) in 72% of people. A basal + prandial insulin regimen was used by 51% of people with an average daily dose of 52 IU insulin and a mean HbA¡ø1c of 8.1%. Premixed insulin was used by 27% of people with an average dose of 38 IU insulin and a mean HbA¡ø1c of 8.5%. Only 9% of people were using a basal insulin alone (average dose 31 IU insulin and mean HbA¡ø1c 8.5%) and 4% a prandial insulin alone (average dose 29 IU insulin and mean HbA¡ø1c 7.6%). As can be seen, despite the findings of the DCCT and the recommendations of the ADA, the majority of people recruited have not achieved the recommended treatment goals for HbA¡ø1c and FBG. It is thus apparent that more efficient guidance and education be made available to improve treatment outcomes in type 1 diabetic patients world wide.